Giulia Serra, MD

Child Neuropsychiatry Unit, Department of Neuroscience, IRCCS Bambino Gesù Pediatric Hospital, Rome, Italy; Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts

JCP
Esmethadone (REL-1017) in Patients with Major Depressive Disorder and Antidepressant Tachyphylaxis
Original Research

October 6, 2025

Esmethadone may be a potentially safe and effective adjunctive treatment for patients with MDD and antidepressant tachyphylaxis.
, , , et al
JCP
Effect of Time From Onset of MDD on Response to Esmethadone
Original Research

May 13, 2024

Esmethadone 25 and 50 mg were more effective in reducing depression scale scores in patients who had a shorter time since their first major depressive episode.
, , , et al
PCC
REL-1017 Effects on Cognition in MDD
Original Research

February 14, 2023

REL-1017 improved subjective measures of cognitive impairment, in addition to improving total MADRS and SDQ scores.
, , , et al
JCP
Article

May 27, 2015

, , , et al
JCP
Original Research

January 28, 2015

, , , et al

Watch the New PsychCase360

Explore two real-world schizophrenia cases
Promotional banner for a video titled “Choosing the Right LAI for Patients With Schizophrenia” featuring headshots of Roueen Rafeyan, MD, and Melissa Vitale, PMHNP, with a “Watch Now” button.

Subscribe to read
more articles

Subscribe